60d FRN published

36207

Federal Register / Vol. 85, No. 115 / Monday, June 15, 2020 / Notices
Proposed Project
DOP Cross-Site Evaluation of
Overdose Data to Action Program–
New—National Center for Injury
Prevention and Control (NCIPC),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Overdose Data to Action Program
(OD2A) is a comprehensive, national
overdose prevention program developed
by CDC’s NCIPC. The purpose of the
OD2A program is to support funded
jurisdictions in obtaining high quality,
complete, and timely data on opioid
prescribing and overdoses, and to use
those data to inform prevention and
response efforts. The OD2A (CDC–RFA–
CE19–1904) funds a total of 66
recipients (state and local health

jurisdictions. The outcome evaluation
will assess short term (e.g., increased
awareness and coordination of linkages
to care) and intermediate (e.g., increased
provider, health system, and payer
awareness of and supports for guidelineconcordant opioid prescribing, nonopioid medications, and nonpharmacological treatments) outcomes.
Data collected from this evaluation
will be used by the CDC to obtain valid
information regarding how recipients
operationalized and implemented their
chosen prevention activities, assess the
impact of OD2A and different
components of OD2A on the trajectory
of the opioid epidemic, and through the
provision of these data back to the
recipients, improve the implementation
and impact of further OD2A prevention
activities.

departments) to implement surveillance
and prevention strategies, through a
three-year cooperative agreement. OD2A
funded recipients consist of 47 state-, 16
city/county-, and three district/territorylevel jurisdictions.
The purpose of this information
collection is to assess the
implementation and the effectiveness of
the OD2A program activities and
identify the conditions under which
these activities are most effective.
Activities include key informant
interviews (KII) and focus groups (FG),
and are focused on the tools needed to
evaluate the unique OD2A program.
The implementation evaluation will
identify the barriers and facilitators
associated with deploying several
prevention activities targeting specific
populations within specific

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent

Average
burden per
response

Total burden
(hours)

Form name

Jurisdictions implementing OD2A
program (e.g., PMs, PIs, SSLs,
PSLs, Partners, or Stakeholders).

Key Informant Interview Guides .......
Focus Group Guides ........................

288
252

1
1

60
90

288
378

Permission to be recorded ...............
Interview Recruitment Email ............
Focus Group Recruitment Email ......
Interview Recruitment Reminder
Email.
Focus Group Recruitment Reminder
Email.
Post-information Collection Follow
up Email.

540
288
252
288

1
1
1
1

5
5
5
5

45
24
21
24

252

1

5

21

540

1

5

45

...........................................................

........................

........................

........................

846

Total ...........................................

Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–12808 Filed 6–12–20; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–20–0666; Docket No. CDC–2020–
0065]

Proposed Data Collection Submitted
for Public Comment and
Recommendations
jbell on DSKJLSW7X2PROD with NOTICES

Number of
respondents

Type of respondent

Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:

The Centers for Disease
Control and Prevention (CDC), as part of

SUMMARY:

VerDate Sep<11>2014

17:04 Jun 12, 2020

Jkt 250001

its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on the
CDC’s National Healthcare Safety
Network (NHSN). NHSN is a public
health surveillance system that collects,
analyzes, reports, and makes available
data for monitoring, measuring, and
responding to healthcare associated
infections (HAIs), antimicrobial use and
resistance, blood transfusion safety
events, and the extent to which
healthcare facilities adhere to infection
prevention practices and antimicrobial
stewardship.
CDC must receive written
comments on or before August 14, 2020.

DATES:

PO 00000

Frm 00024

Fmt 4703

Sfmt 4703

You may submit comments,
identified by Docket No. CDC–2020–
0065 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
ADDRESSES:

E:\FR\FM\15JNN1.SGM

15JNN1

36208

Federal Register / Vol. 85, No. 115 / Monday, June 15, 2020 / Notices

Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7570; Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected; and
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
5. Assess information collection costs.

jbell on DSKJLSW7X2PROD with NOTICES

Proposed Project
National Healthcare Safety Network
(NHSN) (OMB Control No. 0920–
0666)—Revision—National Center for
Emerging and Zoonotic Infection
Diseases (NCEZID), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
The Division of Healthcare Quality
Promotion (DHQP), National Center for
Emerging and Zoonotic Infectious
Diseases (NCEZID), Centers for Disease
Control and Prevention (CDC) collects
data from healthcare facilities in the
National Healthcare Safety Network
(NHSN) under OMB Control Number
0920–0666. NHSN provides facilities,

VerDate Sep<11>2014

17:04 Jun 12, 2020

Jkt 250001

states, regions, and the nation with data
necessary to identify problem areas,
measure the progress of prevention
efforts, and ultimately eliminate
healthcare-associated infections (HAIs)
nationwide. NHSN allows healthcare
facilities to track blood safety errors and
various healthcare-associated infection
prevention practice methods such as
healthcare personnel influenza vaccine
status and corresponding infection
control adherence rates.
NHSN currently has six components:
Patient Safety (PS), Healthcare
Personnel Safety (HPS), Biovigilance
(BV), Long-Term Care Facility (LTCF),
Outpatient Procedure (OPC), and the
Dialysis Component. NHSN’s planned
Neonatal Component is expected to
launch during the winter of 2020/2021.
This component will focus on
premature neonates and the healthcareassociated events that occur as a result
of their prematurity. This component
will be released with one module,
which includes Late Onset-Sepsis and
Meningitis. Late-onset sepsis (LOS) and
Meningitis are common complications
of extreme prematurity. These infections
are usually serious, causing a
prolongation of hospital stay, increased
cost, and risk of morbidity and
mortality. The data for this module will
be electronically submitted, and manual
data entry will not be available. This
will allow more hospital personnel to be
available to care for patients and will
reduce annual burden across healthcare
facilities. Additionally, LOS data will be
utilized for prevention initiatives.
Data reported under the Patient Safety
Component are used to determine the
magnitude of the healthcare-associated
adverse events and trends in the rates of
the events, in the distribution of
pathogens, and in the adherence to
prevention practices. Data will help
detect changes in the epidemiology of
adverse events resulting from new
medical therapies and changing patient
risks. Additionally, reported data is
being used to describe the epidemiology
of antimicrobial use and resistance and
to better understand the relationship of
antimicrobial therapy to this rising
problem.
Approved as a New Emergency ICR
(National Healthcare Safety Network
(NHSN) Patient Impact Module for
Coronavirus (COVID–19) Surveillance
in Healthcare Facilities, OMB Control
No. 0920–1290), NHSN launched a
COVID–19 Module in the Patient Safety
Component on March 27th, 2020. This
Module is designed to collect facilitylevel COVID–19 data on cases, deaths,
capacity, healthcare worker staffing
shortages, and personal protective
equipment and supplies from hospitals

PO 00000

Frm 00025

Fmt 4703

Sfmt 4703

on a daily basis. Facility-level data
collected through NSHN as part of the
COVID–19 Module are being made
available to a broader set of Federal,
state, and local agency data users than
data typically collected by NHSN.
Specifically, COVID–19 data at the state,
county, territory, and facility level
submitted to NHSN will continue to be
used for public health emergency
response activities by CDC’s emergency
COVID–19 response, by the U.S.
Department of Health and Human
Services’ (HHS’) COVID–19 tracking
system maintained in the Office of the
Assistant Secretary of Preparedness and
Response as part of the National
Response Coordination Center at the
Federal Emergency Management Agency
(FEMA), and by the White House
Coronavirus Task Force.
Under the Healthcare Personnel
Safety Component, protocols and data
on events—both positive and adverse—
are used to determine (1) the magnitude
of adverse events in healthcare
personnel, and (2) compliance with
immunization and sharps injuries safety
guidelines. Under the Biovigilance
Component, data on adverse reactions
and incidents associated with blood
transfusions are reported and analyzed
to provide national estimates of adverse
reactions and incidents. Under the
Long-Term Care Facility Component,
data is captured from skilled nursing
facilities. Reporting methods under the
LTCF component have been created by
using forms from the PS Component as
a model with modifications to
specifically address the specific
characteristics of LTCF residents and
the unique data needs of these facilities
reporting into NHSN. A new form has
been introduced for field testingRespiratory Tract Infection (RTI)—not to
be used by NHSN users, but as part of
an EIP project with 4 EIP sites. Form
title will be Denominators for
Healthcare Associated Infections
(HAIs): Respiratory Tract Infections. The
purpose of this form is to allow testing
prior to introducing a new module and
forms to NHSN users. The CDC’s
Epidemiology Research & Innovations
Branch (ERIB) team will use the form to
perform field testing of variables to
explore the utilization, applicability,
and data collection burden associated
with these variables. This process will
inform areas of improvement prior to
incorporating the new module,
including protocol, forms, and
instructions into NHSN. The estimated
burden for this form is 20 minutes,
which is based on a similar
denominator form. Also approved under
New Emergency ICR 0920–1290, NHSN

E:\FR\FM\15JNN1.SGM

15JNN1

36209

Federal Register / Vol. 85, No. 115 / Monday, June 15, 2020 / Notices
launched a COVID–19 Module in the
Long-Term Care Component April 27th,
2020. As with the COVID–19 Module in
the PS Component, the LTC COVID–19
Module is designed to collect facilitylevel COVID–19 data on cases, deaths,
capacity, healthcare worker staffing
shortages, and personal protective
equipment and supplies from long-term
care facilities on at least a weekly basis.
Facility-level data collected through
NSHN as part of the COVID–19 Module
are being made available to a broader set
of Federal, state, and local agency data
users than data typically collected by
NHSN. Specifically, COVID–19 data at
the state, county, territory, and facility
level submitted to NHSN will continue
to be used for public health emergency
response activities by CDC’s emergency
COVID–19 response, by the U.S.
Department of Health and Human
Services’ (HHS’) COVID–19 tracking
system maintained in the Office of the
Assistant Secretary of Preparedness and
Response as part of the National
Response Coordination Center at the
Federal Emergency Management Agency
(FEMA), and by the White House
Coronavirus Task Force.
The Dialysis Component offers a
simplified user interface for dialysis
users to streamline their data entry and
analyses processes as well as provide
options for expanding in the future to
include dialysis surveillance in settings
other than outpatient facilities. The
Outpatient Procedure Component (OPC)
gathers data on the impact of infections
and outcomes related to operative
procedures performed in Ambulatory
Surgery Centers (ASCs). The OPC is
used to monitor two event types: Same
Day Outcome Measures and Surgical
Site Infections (SSIs). NHSN has
increasingly served as the operating
system for HAI reporting compliance

mandate. Facilities that fail to report
quality measure data are subject to
partial payment reduction in the
applicable Medicare Fee-for-Service
payment system. CMS links their
quality reporting to payment for
Medicare-eligible acute care hospitals,
inpatient rehabilitation facilities, longterm acute care facilities, oncology
hospitals, inpatient psychiatric
facilities, dialysis facilities, and
ambulatory surgery centers. Facilities
report HAI data and healthcare
personnel influenza vaccination
summary data to CMS via NHSN as part
of CMS’s quality reporting programs to
receive full payment. Still, many
healthcare facilities, even in states
without HAI reporting legislation,
submit limited HAI data to NHSN
voluntarily. NHSN’s data collection
updates continue to support the
incentive programs managed by CMS.
For example, survey questions support
requirements for CMS’ quality reporting
programs. Additionally, CDC has
collaborated with CMS on a voluntary
National Nursing Home Quality
Collaborative, which focuses on
recruiting nursing homes to report HAI
data to NHSN and to retain their
continued participation. This project
has resulted in a significant increase in
long-term care facilities reporting to
NHSN.
The ICR previously approved in
December of 2019 for 5,352,360
responses; 3,113,631 burden hours. The
proposed changes in this new ICR
include revisions to eight data
collection forms and the addition of ten
new forms for a total of 86 proposed
data collection forms. In this Revision,
CDC requests OMB approval for an
estimated 2,365,743 annual burden
hours.

through legislation established by the
states. As of April 2020, 36 states, the
District of Columbia and the City of
Philadelphia, Pennsylvania have opted
to use NHSN as their primary system for
mandated reporting. Reporting
compliance is completed by healthcare
facilities in their respective
jurisdictions, with emphasis on those
states and municipalities acquiring
varying consequences for failure to use
NHSN. Additionally, healthcare
facilities in five U.S. territories (Puerto
Rico, American Samoa, the U.S. Virgin
Islands, Guam, and the Northern
Mariana Islands) are voluntarily
reporting to NHSN. Additional
territories are projected to follow with
similar use of NHSN for reporting
purposes.
NHSN’s data is used to aid in the
tracking of HAIs and guide infection
prevention activities/practices that
protect patients. The Centers for
Medicare and Medicaid Services (CMS)
and other payers use these data to
determine incentives for performance at
healthcare facilities across the US and
surrounding territories, and members of
the public may use some protected data
to inform their selection among
available providers. Each of these
parties is dependent on the
completeness and accuracy of the data.
CDC and CMS work closely and are
fully committed to ensuring complete
and accurate reporting, which are
critical for protecting patients and
guiding national, state, and local
prevention priorities.
CMS collects some HAI data and
healthcare personnel influenza
vaccination summary data, which is
done on a voluntary basis as part of its
Fee-for-Service Medicare quality
reporting programs, while others may
report data required by a federal

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

jbell on DSKJLSW7X2PROD with NOTICES

Form No. & name

57.100 NHSN Registration Form .....................................................................
57.101 Facility Contact Information .................................................................
57.103 Patient Safety Component—Annual Hospital Survey .........................
57.105 Group Contact Information ..................................................................
57.106 Patient Safety Monthly Reporting Plan ...............................................
57.108 Primary Bloodstream Infection (BSI) ...................................................
57.111 Pneumonia (PNEU) .............................................................................
57.112 Ventilator-Associated Event ................................................................
57.113 Pediatric Ventilator-Associated Event (PedVAE) ................................
57.114 Urinary Tract Infection (UTI) ................................................................
57.115 Custom Event ......................................................................................
57.116 Denominators for Neonatal Intensive Care Unit (NICU) .....................
57.117 Denominators for Specialty Care Area (SCA)/Oncology (ONC) .........
57.118 Denominators for Intensive Care Unit (ICU)/Other locations (not
NICU or SCA) ..............................................................................................
57.120 Surgical Site Infection (SSI) ................................................................

VerDate Sep<11>2014

17:04 Jun 12, 2020

Jkt 250001

PO 00000

Frm 00026

Fmt 4703

Sfmt 4703

Number of
responses per
respondent

Average
burden per
response
(min./hour)

Total burden
(hours)

2,000
2,000
6,765
1,000
7,821
5,775
1,800
5,463
334
6,000
600
1,100
500

1
1
1
1
12
5
2
8
1
5
91
12
12

5/60
10/60
55/60
5/60
15/60
38/60
30/60
28/60
30/60
20/60
35/60
4/60
5/60

167
333
6,201
83
23,463
18,288
18,288
20,395
167
10,000
31,850
880
503

5,500
6,000

60
9

5/60
35/60

27,665
31,500

E:\FR\FM\15JNN1.SGM

15JNN1

36210

Federal Register / Vol. 85, No. 115 / Monday, June 15, 2020 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
respondents

jbell on DSKJLSW7X2PROD with NOTICES

Form No. & name

57.121 Denominator for Procedure .................................................................
57.122 HAI Progress Report State Health Department Survey ......................
57.123 Antimicrobial Use and Resistance (AUR)-Microbiology Data Electronic Upload Specification Tables ..............................................................
57.124 Antimicrobial Use and Resistance (AUR)-Pharmacy Data Electronic
Upload Specification Tables ........................................................................
57.125 Central Line Insertion Practices Adherence Monitoring ......................
57.126 MDRO or CDI Infection Form ..............................................................
57.127 MDRO and CDI Prevention Process and Outcome Measures Monthly Monitoring .................................................................................................
57.128 Laboratory-identified MDRO or CDI Event ..........................................
57.129 Adult Sepsis .........................................................................................
57.130 COVID–19 Module: Patient Impact and Hospital Capacity .................
57.131 COVID–19 Module: Healthcare Worker Staffing .................................
57.132 COVID–19 Module: Supplies ..............................................................
57.135 Late Onset Sepsis/Meningitis Denominator Form: Data Table for
monthly electronic upload ............................................................................
57.136 Late Onset Sepsis/Meningitis Event Form: Data Table for Monthly
Electronic Upload .........................................................................................
57.137 Long-Term Care Facility Component—Annual Facility Survey ...........
57.138 Laboratory-identified MDRO or CDI Event for LTCF ..........................
57.139 MDRO and CDI Prevention Process Measures Monthly Monitoring
for LTCF .......................................................................................................
57.140 Urinary Tract Infection (UTI) for LTCF ................................................
57.141 Monthly Reporting Plan for LTCF ........................................................
57.142 Denominators for LTCF Locations ......................................................
57.143 Prevention Process Measures Monthly Monitoring for LTCF .............
57.144 LTCF COVID–19 Module: Resident Impact and Facility Capacity .....
57.145 LTCF COVID–19 Module: Staff and Personnel Impact ......................
57.146 LTCF COVID–19 Module: Supplies and PPE .....................................
57.147 LTCF COVID–19 Module: Ventilator Capacity and Supplies ..............
57.150 LTAC Annual Survey ...........................................................................
57.151 Rehab Annual Survey .........................................................................
57.200 Healthcare Personnel Safety Component Annual Facility Survey ......
57.203 Healthcare Personnel Safety Monthly Reporting Plan ........................
57.204 Healthcare Worker Demographic Data ...............................................
57.205 Exposure to Blood/Body Fluids ...........................................................
57.206 Healthcare Worker Prophylaxis/Treatment ..........................................
57.207 Follow-Up Laboratory Testing .............................................................
57.210 Healthcare Worker Prophylaxis/Treatment-Influenza ..........................
57.300 Hemovigilance Module Annual Survey ................................................
57.301 Hemovigilance Module Monthly Reporting Plan .................................
57.303 Hemovigilance Module Monthly Reporting Denominators ..................
57.305 Hemovigilance Incident .......................................................................
57.306 Hemovigilance Module Annual Survey—Non-acute care facility ........
57.307 Hemovigilance Adverse Reaction—Acute Hemolytic Transfusion Reaction ............................................................................................................
57.308 Hemovigilance Adverse Reaction—Allergic Transfusion Reaction .....
57.309 Hemovigilance Adverse Reaction—Delayed Hemolytic Transfusion
Reaction .......................................................................................................
57.310 Hemovigilance Adverse Reaction—Delayed Serologic Transfusion
Reaction .......................................................................................................
57.311 Hemovigilance Adverse Reaction—Febrile Non-hemolytic Transfusion Reaction ............................................................................................
57.312 Hemovigilance Adverse Reaction—Hypotensive Transfusion Reaction ................................................................................................................
57.313 Hemovigilance Adverse Reaction—Infection ......................................
57.314 Hemovigilance Adverse Reaction—Post Transfusion Purpura ...........
57.315 Hemovigilance Adverse Reaction—Transfusion Associated Dyspnea
57.316 Hemovigilance Adverse Reaction—Transfusion Associated Graft vs.
Host Disease ................................................................................................
57.317 Hemovigilance Adverse Reaction—Transfusion Related Acute Lung
Injury .............................................................................................................
57.318 Hemovigilance Adverse Reaction—Transfusion Associated Circulatory Overload .........................................................................................
57.319 Hemovigilance Adverse Reaction—Unknown Transfusion Reaction ..
57.320 Hemovigilance Adverse Reaction—Other Transfusion Reaction ........
57.400 Outpatient Procedure Component—Annual Facility Survey ...............
57.401 Outpatient Procedure Component—Monthly Reporting Plan .............

VerDate Sep<11>2014

17:04 Jun 12, 2020

Jkt 250001

PO 00000

Frm 00027

Fmt 4703

Number of
responses per
respondent

Average
burden per
response
(min./hour)

Total burden
(hours)

6,000
55

602
1

10/60
28/60

602,000
26

2,500

12

5/60

1,500

2,000
500
720

12
213
12

5/60
25/60
30/60

2,000
44,375
3,960

5,500
4,800
50
3,117
3,117
3,117

29
79
250
540
540
540

15/60
20/60
25/60
25/60
25/60
25/60

39,875
126,400
5,208
701,325
701,325
701,325

300

12

5/60

300

300
3,079
1,998

4
1
24

5/60
1/60
12/60

100
51
9,590

1,998
339
2,011
339
130
14,674
14,674
14,674
14,674
620
1,340
50
........................
50
50
50
50
50
500
500
500
500
500

12
12
12
12
12
26
26
26
26
1
1
1
1
200
50
30
50
50
1
12
12
10
1

12/60
12/60
12/60
250/60
12/60
20/60
15/60
5/60
5/60
10/60
10/60
480/60
5/60
20/60
60/60
15/60
15/60
10/60
85/60
1/60
70/60
10/60
35/60

4,795
814
4,826
814
312
127,175
95,381
31,794
31,794
10
625
400
........................
3,333
2,500
375
625
417
708
100
7,000
833
292

500
500

4
4

20/60
20/60

667
667

500

1

20/60

167

500

2

20/60

333

500

4

20/60

667

500
500
500
500

1
1
1
1

20/60
20/60
20/60
20/60

167
167
167
167

500

1

20/60

167

500

1

20/60

167

500
500
500
700
700

2
1
1
1
12

20/60
20/60
20/60
10/60
15/60

333
167
167
117
2,100

Sfmt 4703

E:\FR\FM\15JNN1.SGM

15JNN1

36211

Federal Register / Vol. 85, No. 115 / Monday, June 15, 2020 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Average
burden per
response
(min./hour)

Total burden
(hours)

57.402 Outpatient Procedure Component Same Day Outcome Measures ....
57.403 Outpatient Procedure Component—Monthly Denominators for Same
Day Outcome Measures ..............................................................................
57.404 Outpatient Procedure Component—SSI Denominator ........................
57.405 Outpatient Procedure Component—Surgical Site (SSI) Event ...........
57.500 Outpatient Dialysis Center Practices Survey ......................................
57.501 Dialysis Monthly Reporting Plan ..........................................................
57.502 Dialysis Event ......................................................................................
57.503 Denominator for Outpatient Dialysis ....................................................
57.504 Prevention Process Measures Monthly Monitoring for Dialysis ..........
57.505 Dialysis Patient Influenza Vaccination .................................................
57.506 Dialysis Patient Influenza Vaccination Denominator ...........................
57.507 Home Dialysis Center Practices Survey .............................................

200

1

40/60

133

200
700
700
7,200
7,200
7,200
7,200
1,730
615
615
430

400
100
5
1
12
30
30
12
50
5
1

40/60
40/60
40/60
127/60
5/60
25/60
10/60
75/60
10/60
10/60
30/60

53,333
46,667
2,333
15,240
7,200
90,000
14,400
25,950
5,125
513
215

Total ..........................................................................................................

........................

........................

........................

2,365,743

Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–12809 Filed 6–12–20; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day-20–1186]

Agency Forms Undergoing Paperwork
Reduction Act Review

jbell on DSKJLSW7X2PROD with NOTICES

Number of
responses per
respondent

Number of
respondents

Form No. & name

In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled Information
Collection for Tuberculosis Data from
Referring Entities to CureTB to the
Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on December 23, 2019 to obtain
comments from the public and affected
agencies. CDC did not receive comments
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including

VerDate Sep<11>2014

17:04 Jun 12, 2020

Jkt 250001

whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Information Collection for
Tuberculosis Data from Referring
Entities to CureTB (OMB Control No.

PO 00000

Frm 00028

Fmt 4703

Sfmt 4703

0920–1186, Exp. 06/30/2020)—
Revision—National Center for Emerging
Zoonotic and Infectious Diseases
(NCEZID), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
CureTB at the Centers for Disease
Control and Prevention (CDC) works
with domestic and international
programs to protect the U.S. public by
preventing tuberculosis (TB) disease
transmission domestically and
internationally, as well as preventing
the development of drug resistant TB.
These goals are accomplished through
CureTB referral and continuity of care
services for mobile TB patients.
Lack of treatment adherence and
inappropriate selection of medications
are prime reasons for the continued
emergence and spread of resistant
strains of tuberculosis. To combat this,
CureTB ensures that patients
understand how to remain adherent to
treatment regimens, despite moving
between nations. CureTB also provides
information to the health care team that
will be continuing care about each
patient’s TB strain and tailored
medication regimen. CureTB gathers
demographic and clinical information
for each patient and connects that
individual to appropriate clinical care.
This information is also provided on a
real-time basis to medical providers and
public health authorities in receiving
nations so that follow-up with the
patient can be expedited.
The respondents are local health
departments (LHD) or Immigration and
Customs Enforcement (ICE) detention
centers within the United States and
foreign national TB programs or
healthcare facilities in other countries
that provide diagnostic and treatment
services to individuals affected by TB.

E:\FR\FM\15JNN1.SGM

15JNN1